Ovarian stimulation: Today and tomorrow

Current Pharmaceutical Biotechnology

Volumn 13, Issue 3, 2012, Pages 392-397

  Fatemi, H M ^a   Blockeel, C ^a   Devroey, P ^a  

^a CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

Corifollitropin alfa; Future of IVF; GnRH agonist; GnRH antagonist; Gonadotropins; Ovarian stimulation

Indexed keywords

CHORIONIC GONADOTROPIN; CORIFOLLITROPIN ALFA; ESTRADIOL; ESTROGEN; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

ABDOMINAL PAIN; ARTICLE; CLINICAL PROTOCOL; CRYOPRESERVATION; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; EMBRYO TRANSFER; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; FREEZE THAWING; HORMONAL THERAPY; HOT FLUSH; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; MOOD SWING; MULTIPLE PREGNANCY; NAUSEA; NIGHT SWEAT; NONHUMAN; OVARIAN STIMULATION; OVARY; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVULATION; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

CRYOPRESERVATION; FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; INFERTILITY, FEMALE; OVULATION INDUCTION;

EID: 84857759397     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799362007     Document Type: Article

References (70)

1. Boivin, J.; Bunting, L.; Collins, J.; Nygren, K. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum. Reprod., 2007, 22(6), 1506-1512.
2. van Santbrink, E.; Hop, W.; van Dessel, T.; de Jong, F.; Fauser, B. Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. Fertil Steril., 1995 64(1), 37-43.
3. Sullivan, M.; Stewart-Akers, A.; Krasnow, J.; Berga, S.; Zeleznik, A. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J. Clin. Endocrinol. Metab., 1999, 84(1), 228-232.
4. Fiddes, J.; Talmadge, K. Structure, expression, and evolution of the genes for the human glycoprotein hormones. Recent Prog. Horm. Res., 1984, 40, 43-78.
5. Lalloz, M.; Detta, A.; Clayton, R. Gonadotropin-releasing hormone desensitization preferentially inhibits expression of the luteinizing hormone beta-subunit gene in vivo. Endocrinology, 1988, 122(4), 1689-1694.
6. Morell, A.; Gregoriadis, G.; Scheinberg, I.; Hickman, J.; Ashwell, G. The role of sialic acid in determining the survival of glycoproteins in the circulation. J. Biol. Chem., 1971, 246(5), 1461-1467.
7. Edwards, R.; Steptoe, P. Induction of follicular growth, ovulation and luteinization in the human ovary. J. Reprod. Fertil. Suppl., 1975, (22), 121-163.
8. Lunenfeld, B. Historical perspectives in gonadotrophin therapy. Hum. Reprod. Update, 2004, 10(6), 453-467.
9. Brown, J. Pituitary control of ovarian function: concepts derived from gonadotrophin therapy. Aust. N. Z. J. Obstet. Gynaecol., 1978, 18(1), 47-54.
10. Baird 1987
11. Fauser, B.; van Heusden, A. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endcr. Rev., 1997, 18(1), 71-106.
12. Coomarasamy A.; Afnan M.; Cheema D.; van der Veen F.; Patrick M.; Bossuyt M. and van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis Human Reproduction 2008, Vol.23, (2) pp. 310-315. doi:10.1093/humrep/dem305 Advance Access publication on December 3, 2007
13. Donini, P; Montezemolo, R. Rassegna di Clinica, Terapia e Scienze Affini. In A publication of the Biologic Laboratories of the Instituto Serono, 1949, 48, 3-28.
14. Howles, C.; Barri, P.; Cittadini, E. Metrodin HP Clinical experiences with a new highly purified follicle stimulating hormone preparation suitable for subcutaneous administration. In Lunenfeld, B. ed., FSH Alone in Ovulation Induction. Parthenon Publishing Group, New York, USA, 1992, 45-61.
15. Lunefeld B. Historical perspectives in gonadotrophin therapy. Hum. Reprod. Update, 2004, 10(6): 453-467.
16. Hayden, C.; Rutherford, A.; Balen, A. Induction of ovulation with the use of a starting dose of 50 units of recombinant human folliclestimulating hormone (Puregon). Fertil. Steril., 1999, 71(1), 106-108.
17. Daya S.; Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. Cochrane Database Syst Rev., 2000, (4), CD002810
18. Macklon, N.; Stouffer, R.; Giudice, L.; Fauser, B. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr. Rev., 2006, 27(2), 170-207.
19. Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev., 2000,(2) CD001299
20. Lambalk, C.; Leader, A.; Olivennes, F.; Fluker, M.; Andersen, A.; Ingerslev, J.; Khalaf, Y.; Avril, C.; Belaisch-Allart, J.; Roulier, R.; Mannaerts, B. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. Hum. Reprod., 2006, 21(3),632-639.
21. The European Orgalutran Study Group; Borm, G.; Mannaerts, B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum. Reprod., 2000, 15(7), 1490-1498.
22. The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum. Reprod., 2001, 16(4), 644-651.
23. Fluker, M.; Grifo, J.; Leader, A.; Levy, M.; Meldrum, D.; Muasher, S.; Rinehart, J.; Rosenwaks, Z.; Scott, R.; Schoolcraft, W.; Shapiro, D.; North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil. Steril., 2001, 75(1), 38-45.
24. Al-Inany, H.; Abou-Setta, A.; Aboulghar, M. Gonadotrophinreleasing hormone antagonists for assisted conception: a Cochrane review. Reprod. Biomed. Online, 2007, 14(5), 640-649.
25. Qublan, H.; Amarin, Z.; Tahat, Y.; Smadi, A.; Kilani, M. Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact. Hum. Reprod., 2006, 21(3), 640-644.
26. Fauser, B.; Devroey, P.; Yen, S.; Gosden, R.; Crowley, W.; Baird, D.; Bouchard, P. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum. Reprod., 1999, 14(11), 2681-2686.
27. Brinsden, P.; Wada, I.; Tan, S.; Balen, A.; Jacobs, H. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br. J. Obstet. Gynaecol., 1995, 102(10), 767-772.
28. Papanikolaou, E.; Pozzobon, C.; Kolibianakis, E.; Camus, M.; Tournaye, H.; Fatemi, H.; Van Steirteghem, A.; Devroey, P. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil. Steril., 2006, 85(1), 112-120.
29. Kolibianakis, E.; Collins, J.; Tarlatzis, B.; Devroey, P.; Diedrich, K.; Griesinger, G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and metaanalysis. Hum. Reprod. Update, 2006, 12(6), 651-671.
30. Griesinger G.; Kolibianakis E.M.; Venetis C.; Diedrich K.; Tarlatzis B. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril., 2010, 94(6), 2382-2384.
31. Fanchin R.; Salomon L.; Castelo-Branco A.; Olivennes F.; Frydman N.; Frydman R. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum. Reprod., 2003, 18(12)2698-2703.
32. Al-Inany, H.; Abou-Setta, A.; Aboulghar, M.; Mansour, R.; Serour, G. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod. Biomed. Online, 2008, 16(1), 81-88.
33. Coomarasamy, A.; Afnan, M.; Cheema, D.; van der Veen, F.; Bossuyt, P.; van Wely, M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum. Reprod., 2008, 23(2), 310-315.
34. Bosch, E.; Vidal, C.; Labarta, E.; Simon, C.; Remohi, J.; Pellicer, A. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study. Hum. Reprod., 2008, 23(10), 2346-2351.
35. Kolibianakis, E.; Albano, C.; Camus, M.; Tournaye, H.; Van Steirteghem, A.; Devroey, P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil. Steril., 2004, 82(1): 102-107.
36. Smitz, J.; Andersen, A.; Devroey, P.; Arce, JC.; Merit Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum. Reprod., 2007, 22(3), 676-687.
37. Kyrou, D.; Popovic-Todorovic, B.; Fatemi, H.; Bourgain, C.; Haentjens, P.; Van Landuyt, L.; Devroey, P. Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec- FSH/GnRH antagonist? Hum. Reprod., 2009, 24(11), 2902-2909.
38. Van Vaerenbergh, I.; Fatemi, H.; Blockeel, C.; Van Lommel, L.; In't Veld, P.; Schuit, F.; Kolibianakis, E.; Devroey, P.; Bourgain, C. Progesterone rise on the day of hCG administration in GnRH antagonist/ rec-FSH stimulated cycles affects endometrial gene expression. Reprod. Biomed. Online, 2010, in press.
39. Andersen, AN.; Devroey, P.; Arce, JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum. Reprod., 2006, 21(12), 3217-3227.
40. Mannaerts, B.; Shoham, Z.; Schoot, D.; Bouchard, P.; Harlin, J.; Fauser, B.; Jacobs, H.; Rombout, F.; Coelingh Bennink, H. Singledose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropindeficient volunteers. Fertil. Steril., 1993, 59(1),108-114.
41. Beckers, N.; Macklon, N.; Devroey, P.; Platteau, P.; Boerrigter, P.; Fauser, B. First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertil. Steril., 2003, 79(3), 621-623.
42. Boime, I.; Ben-Menahem, D. Glycoprotein hormone structurefunction and analog design. Recent Prog. Horm. Res., 1999, 54, 271-288.
43. Devroey, P.; Boostanfar, R.; Koper, N.; Mannaerts, B.; Ijzerman-Boon, P.; Fauser, B.; ENGAGE Investigators. A double-blind, noninferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum. Reprod., 2009, 24(12), 3063-3072.
44. Fatemi, H.; Popovic-Todorovic, B.; Devroey, P. Drug Profile Long-acting FSH analogue: Corifollitropin-α to sustain multifollicular growth during controlled ovarian stimulation. Exp. Rev. Obstet. Gynecol., 2009, 4(6), 601-605.
45. Fatemi, H.; Oberyé, J.; Popovic-Todorovic, B.; Witjes, H.; Mannaerts, B.; Devroey, P. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertil. Steril., 2010, 94(5), 1922-1924.
46. Filicori, M.; Cognigni, G.; Gamberini, E.; Parmegiani, L.; Troilo, E.; Roset, B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil. Steril., 2005, 84(2), 394-401.
47. Blockeel, C.; De Vos, M.; Verpoest, W.; Stoop, D.; Haentjens, P.; Devroey, P. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study. Hum. Reprod., 2009, 24(11), 2910-2916.
48. Kosmas, I.; Zikopoulos, K.; Georgiou, I.; Paraskevaidis, E.; Blockeel, C.; Tournaye, H.; Van Der Elst, J.; Devroey, P. Lowdose HCG may improve pregnancy rates and lower OHSS in antagonist cycles: a meta-analysis. Reprod. Biomed. Online, 2009, 19(5), 619-630.
49. Kessler, M.; Reddy, M.; Shah, R.; Bahl, O. Structures of Nglycosidic carbohydrate units of human chorionic gonadotropin. J. Biol. Chem., 1979, 254, 7901-7908.
50. Damewood, M.; Shen, W.; Zacur, H.; Schlaff, W.; Rock, J.; Wallach, E. Disappearance of exogenously administered human chorionic gonadotropin. Fertil. Steril., 1989, 52(3), 398-400.
51. Mannaerts, B.; Geurts, T.; Odink, J. A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Hum. Reprod., 1998, 13(6), 1461-1464.
52. Itskovitz, J.; Boldes, R.; Levron, J.; Erlik, Y.; Kahana, L.; Brandes, J. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropinreleasing hormone agonist. Fertil. Steril., 1991, 56(2), 213-220.
53. Haning, R.; Strawn, E.; Nolten, W. Pathophysiology of the ovarian hyperstimulation syndrome. Obstet. Gynecol., 1985, 66(2), 220-224.
54. Gonen, Y.; Balakier, H.; Powell, W.; Casper, R. Use of gonadotropin- releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J. Clin. Endocrinol. Metab., 1990, 71(4), 918-922.
55. Fleming, R.; Coutts, J. LHRH analogues can be luteotrophic. Clin. Endocrinol., 1982, 17(6), 593-599.
56. Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet, 1984, 2(8414), 1284-1285.
57. Albano, C.; Smitz, J.; Camus, M.; Riethmüller-Winzen, H.; Siebert-Weigel, M.; Diedrich, K.; Van Steirteghem, A.; Devroey, P. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin- releasing hormone antagonist (Cetrorelix). Hum. Reprod., 1996, 11(10), 2114-2118.
58. Itskovitz-Eldor J.; Kol S.; Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum. Reprod., 2000,15(9),1965-1968.
59. Hoff, J.; Quigley, M.; Yen, S. Hormonal dynamics at midcycle: a reevaluation. J. Clin. Endocrinol. Metab., 1983, 57(4), 792-796.
60. Segal, S.; Casper, R. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertil. Steril., 1992, 57(6), 1254-1258.
61. Balasch, J.; Miró, F.; Burzaco, I.; Casamitjana, R.; Civico, S.; Ballescá, J.; Puerto, B.; Vanrell, J. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum. Reprod., 1995, 10(7), 1678-1683.
62. Strickland, S.; Beers, W. Studies on the role of plasminogen activator in ovulation. In vitro response of granulosa cells to gonadotropins, cyclic nucleotides, and prostaglandins. J. Biol. Chem., 1976, 251(18), 5694-5702.
63. Eppig, JJ. Gonadotropin stimulation of the expansion of cumulus oophori isolated from mice: general conditions for expansion in vitro. J. Exp. Zool., 1979, 208(1), 111-120.
64. Zelinski-Wooten, M.; Hutchison, J.; Hess, D.; Wolf, D.; Stouffer, R. Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist- treated monkeys. Hum. Reprod., 1995, 10(7),1658-1666.
65. Yding Andersen, C. Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod. Biomed. Online, 2002, 5(3), 232-239.
66. Kol S. and Itskovitz-Eldor J. Severe OHSS: yes, there is a strategy to prevent it! Hum Reprod. 2000 Nov;15(11),2266-2267. Review.
67. Kol S. Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent! Hum. Reprod., 2003, 18(7),1557-1558.
68. Orvieto, R. Can we eliminate severe ovarian hyperstimulation syndrome? Hum. Reprod., 2005, 20(2), 320-322.
69. Humaidan, P.; Papanikolaou, E.; Tarlatzis, B. GnRHa to trigger final oocyte maturation: a time to reconsider. Hum. Reprod., 2009, 24(10): 2389-2394.
70. Fatemi, H.; Kyrou, D.; Bourgain, C.; Van den Abbeel, E.; Griesinger, G.; Devroey, P. Cryopreserved-thawed human embryo transfer: spontaneous natural cycle is superior to human chorionic gonadotropin-induced natural cycle. Fertil. Steril., 2010, 94(6), 2054-2058.